Cancer Care
- All Services
- Behavioral Health Services
- Bone & Joint Care
- Cancer Care
- Diabetes & Endocrinology
- Emergency Care
- Health & Wellness
- Heart Care
- Hospitalist Care
- Integrative Care
- Intensive Care Unit
- Laboratory
- Maternity & Pregnancy Care
- Neurosciences
- Occupational Health
- Other Services
- Pediatrics
- Primary Care
- Radiology-Imaging
- Respiratory Care
- Surgical Services
- Vascular Services
- Weight Loss Surgery
- Women's Services
- Wound Care Center & Hyperbaric Medicine
Cancer Clinical Research Trials
Cancer Clinical Research Trials
Portsmouth Regional Hospital is committed to offering our patients opportunities to participate in new clinical research trials. This is part of our mission in offering the most advanced services available. These trials are open to those who qualify. Our research nurse coordinators will work with your physicians to discuss trials with you and your family. To learn if you qualify for these or other clinical research trials, please speak with your physician.
| Disease | Trial name | Objective of trial |
|---|---|---|
|
Breast |
ML28257 – An Observational Cohort Study of Treatment Patterns and Outcomes in Patients with HER2 Positive (HER2+) Metastatic Breast Cancer |
To describe temporal trends in treatment patterns as well as sequencing of treatments and clinical outcomes in patients with HER2+ MBC; to examine the comparative effectiveness and safety of various HER2- targeted treatment regimens, or their combinations, in patients with HER2+ MBC. |
| Colorectal | GI 134 – A Phase II Study of FOLFOXIRI Plus Panitumumab Followed by Evaluation for Resection, in Patients with Metastatic KRAS Wild-Type Colorectal Cancer with Liver Metastases Only | To determine the overall response rate of the combination of FOLFOXIRI plus panitumumab. |
| Colorectal | GI 154 – A Phase II Trial of Single Agent Axitinib as Maintenance Therapy for Patients with First Line Metastatic Colorectal Cancer (mCRC) | To assess survival rates of patients with first-line mCRC treated with maintenance axitinib after initial treatment with FOLFOX plus bevacizumab. |
|
Leukemia
|
CA180330 – Studying Interventions for Managing Patients with Chronic Myeloid Leukemia In ChronIc Phase: The 5-Year Prospective Cohort Study (SIMPLICITY) |
To compare overall survival of ramucirumab DP in combination with docetaxel vs. docetaxel with placebo. |
| Lung - Non-Small Cell | I4T-MC-JVBA – A Randomized, Double-Blind, Phase 3 Study of Docetaxel and Ramucirumab versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression after One Prior Platinum-Based Therapy | To better understand the use of dasatinib and other TKIs in first-line CML in real-world setting; to evaluate patient benefit components of CML treatment; to determine healthcare resources used in CML management. |
| Lung- Non-Small Cell | LUN 183 – A Phase II Trial of Carboplatin, Pemetrexed, and Panitumumab in Patients with Advanced Non-Squamous K-ras Wild Type Non-Small Cell Lung Cancer | To examine the role of panitumumab in combination with carboplatin and pemetrexed in patients with advanced non-squamous wild type K-ras NSCLC. |
| Lymphoma | LYM 75 – Phase II Study of Bendamustine and Ofatumumab in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma Who are Poor Candidates for R-CHOP Chemotherapy | To evaluate the complete response rate in patients with newly diagnosed Stage III-IV DLBCL considered poor candidates for R-CHOP therapy treated with the combination of ofatumumab and bendamustine. |
| Multiple Myeloma | C16010 – A Phase 3, Randomized, Double-Blind, Multicenter Study Comparing Oral MLN9708 plus Lenalidomide and Dexamethasone versus Placebo plus Lenalidomide and Dexamethasone in Adult Patients with Relapsed and/or Refractory Multiple Myeloma | To determine if the addition of oral MLN9708 to lenalidomide and dexamethasone improves progression-free and overall survival in patients with RRMM. |
| Polycythemia Vera | CINC424B2301 – Randomized, Open Label, Multicenter Phase III Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 Tablets Versus Best Available Care (The RESPONSE Trial) | To compare the efficacy of INC424 to Best Available Therapy as assessed by both the absence of phlebotomy eligibility and reduction in spleen volume. |
For more information on Clinical Trials, please go to http://www.clinicaltrials.gov/ct2/info/understand.
Find a Physician
-
Kevin G. Looser, MD, FACS
Atlantic Surgical Associates
330 Borthwick Avenue
Suite 308
Portsmouth, NH 03801
Maps & Directions -
Photo Not Available
Asa J. Nixon, MD, MPH
Radiation Oncology Associates
789 Central Avenue
Dover, NH 3820
Maps & Directions -
Photo Not Available
-
Photo Not Available
-
Photo Not Available
Christine Wasilewski, MD
Hematology and Oncology Center at Portsmouth Regional Hospital
155 Borthwick Avenue
Suite 303
Portsmouth, NH 3801
Maps & Directions
Locations
-
Hematology and Oncology Center at Portsmouth Regional Hospital
Directions
155 Borthwick Avenue
Suite 303
Portsmouth, NH 3801
Related Health Content
Cancer Treatment Support
July 1, 2012
Not only is cancer the second leading cause of death in the United States (after heart disease), its insidious nature gives it a special terror. Most diseases give warning in the form of escalating symptoms, while others strike so suddenly that there’s no time to brood on it. Cancer follows a differ ...
Treatments for Kidney Cancer
September 1, 2012
...
Feature Articles
September 1, 2012
What are the latest treatments for cancer? Should you take part in a clinical trial? What cancer screening tests should you be getting, and how often? What can you do to reduce the side effects of cancer and cancer therapy? Our consumer-focused feature articles address these questions and many other ...
Resource Guide for Breast Cancer
September 1, 2012
...
Chemotherapy for Stomach Cancer
$related_health_item.publish_date
...